Grants per year
Personal profile
Research Interests
Hodgkin's disease, Leukemia, Lymphoma
Certifications and Licenses
| Internal Medicine | |
| Hematology | |
| Medical Oncology |
Training Experience
| 1978 | Internship, University of Chicago |
| 1980 | Residency, University of Chicago Hospitals |
| 1981 | Fellowship, Columbia Presbyterian Hospital in NYC |
| 1982 | Fellowship, Northwestern University, McGaw Medical Center |
Education/Academic qualification
MD, Medicine, University of Pennsylvania
… → 1977
Research interests keywords
- Hematology
- Non-Hodgkin's Lymphoma
Fingerprint
Dive into the research topics where Jane Norma Winter is active. These topic labels come from the works of this person. Together they form a unique fingerprint.
- 1 Similar Profiles
Collaborations and top research areas from the last five years
Recent external collaboration on country/territory level. Dive into details by clicking on the dots or
Grants
- 54 Finished
-
Prot #18157/NU COH19H01: A Phase 2 Front-Line PET/CT-2 Response-Adapted Brentuximab Vedotin and Nivolumab Incorporated and Radiation-Free Management of Early Stage Classical Hodgkin Lymphoma (cHL)
City of Hope National Medical Center, Bristol-Myers Squibb Company
8/12/19 → 8/12/22
Project: Research project
-
Targeting EZH2 in Germinal Center Derived B-Cell Lymphoma
University of Florida, National Cancer Institute
8/1/16 → 7/31/18
Project: Research project
-
Phase II Study of Pidilizumab in Patients with Diffuse Large B-Cell Lymphoma Following First Remission
4/1/15 → 3/31/18
Project: Research project
-
Targeting EZH2 in Germinal Center Derived B-Cell Lymphoma
Joan and Sanford I. Weill Medical College of Cornell University, National Cancer Institute
8/6/14 → 7/31/19
Project: Research project
-
EBV-positive DLBCL frequently harbors somatic mutations associated with clonal hematopoiesis of indeterminate potential
Li, Y., Xu-Monette, Z. Y., Abramson, J., Sohani, A. R., Bhagat, G., Tzankov, A., Visco, C., Zhang, S., Dybkaer, K., Pan, Z., Xu, M., Tam, W., Zu, Y., Hsi, E. D., Hagemeister, F. B., Go, H., van Krieken, J. H., Winter, J. N., Ponzoni, M., Ferreri, A. J. M., & 5 others, Apr 11 2023, In: Blood Advances. 7, 7, p. 1308-1311 4 p.Research output: Contribution to journal › Letter › peer-review
Open Access1 Scopus citations -
Health-related quality of life in early-stage Hodgkin lymphoma: a longitudinal analysis of the ABVD arm in the randomized controlled trial HD.6
Mian, H., Ringash, J., Meyer, R., Hay, A. E., Shepherd, L., Djurfeldt, M., Winter, J. N., Sussman, J., Pater, J., Chen, B. E. & Prica, A., May 2023, In: Supportive Care in Cancer. 31, 5, 256.Research output: Contribution to journal › Article › peer-review
-
Pembrolizumab Added to Ifosfamide, Carboplatin, and Etoposide Chemotherapy for Relapsed or Refractory Classic Hodgkin Lymphoma: A Multi-institutional Phase 2 Investigator-Initiated Nonrandomized Clinical Trial
Bryan, L. J., Casulo, C., Allen, P. B., Smith, S. E., Savas, H., Dillehay, G. L., Karmali, R., Pro, B., Kane, K. L., Bazzi, L. A., Chmiel, J. S., Palmer, B. A., Mehta, J., Gordon, L. I. & Winter, J. N., May 18 2023, In: JAMA Oncology. 9, 5, p. 683-691 9 p.Research output: Contribution to journal › Article › peer-review
1 Scopus citations -
Peri–CAR-T practice patterns and survival predictors for all CAR-T patients and post–CAR-T failure in aggressive B-NHL
Zurko, J., Nizamuddin, I., Epperla, N., David, K., Cohen, J. B., Moyo, T. K., Ollila, T., Hess, B., Roy, I., Ferdman, R., Liu, J., Chowdhury, S. M., Romancik, J., Bhansali, R. S., Harris, E. I., Sorrell, M., Masel, R., Kittai, A. S., Denlinger, N., Sigmund, A. M., & 14 others, Jun 1 2023, In: Blood Advances. 7, 12, p. 2657-2669 13 p.Research output: Contribution to journal › Article › peer-review
Open Access4 Scopus citations -
Phase 2 trial of umbralisib, ublituximab, and venetoclax in patients with relapsed/refractory mantle cell lymphoma
Wallace, D. S., Rowland, C., Hill, B. T., Baran, A. M., Casulo, C., Reagan, P. M., Winter, A., Karmali, R., Winter, J. N., Gordon, L. I., Bui, A., Sportelli, P., Miskin, H. P., Weiss, M. S., Friedberg, J. W., Ma, S. & Barr, P. M., 2023, In: Leukemia and Lymphoma. 64, 9, p. 1579-1582 4 p.Research output: Contribution to journal › Letter › peer-review
Datasets
-
-
Immunoglobulin somatic hypermutation has clinical impact in DLBCL and potential implications for immune checkpoint blockade and neoantigen-based immunotherapies
Xu-Monette, Z. Y. (Contributor), Li, J. (Creator), Xia, Y. (Creator), Crossley, B. (Creator), Bremel, R. D. (Creator), Miao, Y. (Creator), Xiao, M. (Creator), Snyder, T. (Creator), Manyam, G. C. (Contributor), Tan, X. (Contributor), Zhang, H. (Contributor), Visco, C. (Creator), Tzankov, A. (Creator), Dybkaer, K. (Creator), Bhagat, G. (Creator), Tam, W. (Creator), You, H. (Creator), Hsi, E. D. (Creator), Van Krieken, J. H. (Contributor), Huh, J. (Contributor), Ponzoni, M. (Creator), Ferreri, A. J. M. (Creator), Møller, M. B. (Creator), Piris, M. A. (Creator), Winter, J. N. (Creator), Medeiros, J. T. (Creator), Xu, B. (Creator), Li, Y. (Creator), Kirsch, I. (Creator) & Young, K. H. (Creator), figshare, 2019
DOI: 10.6084/m9.figshare.c.4708682.v2, https://springernature.figshare.com/collections/Immunoglobulin_somatic_hypermutation_has_clinical_impact_in_DLBCL_and_potential_implications_for_immune_checkpoint_blockade_and_neoantigen-based_immunotherapies/4708682/2
Dataset
-
MOESM3 of Immunoglobulin somatic hypermutation has clinical impact in DLBCL and potential implications for immune checkpoint blockade and neoantigen-based immunotherapies
Xu-Monette, Z. Y. (Contributor), Li, J. (Creator), Xia, Y. (Creator), Crossley, B. (Creator), Bremel, R. D. (Creator), Miao, Y. (Creator), Xiao, M. (Creator), Snyder, T. (Creator), Manyam, G. C. (Contributor), Tan, X. (Contributor), Zhang, H. (Contributor), Visco, C. (Creator), Tzankov, A. (Creator), Dybkaer, K. (Creator), Bhagat, G. (Creator), Tam, W. (Creator), You, H. (Creator), Hsi, E. D. (Creator), Van Krieken, J. H. (Contributor), Huh, J. (Contributor), Ponzoni, M. (Creator), Ferreri, A. J. M. (Creator), Møller, M. B. (Creator), Piris, M. A. (Creator), Winter, J. N. (Creator), Medeiros, J. T. (Creator), Xu, B. (Creator), Li, Y. (Creator), Kirsch, I. (Creator) & Young, K. H. (Creator), figshare, 2019
DOI: 10.6084/m9.figshare.10027217.v2, https://springernature.figshare.com/articles/MOESM3_of_Immunoglobulin_somatic_hypermutation_has_clinical_impact_in_DLBCL_and_potential_implications_for_immune_checkpoint_blockade_and_neoantigen-based_immunotherapies/10027217/2 and 2 more links, https://springernature.figshare.com/articles/MOESM3_of_Immunoglobulin_somatic_hypermutation_has_clinical_impact_in_DLBCL_and_potential_implications_for_immune_checkpoint_blockade_and_neoantigen-based_immunotherapies/10027217/1, https://springernature.figshare.com/articles/MOESM3_of_Immunoglobulin_somatic_hypermutation_has_clinical_impact_in_DLBCL_and_potential_implications_for_immune_checkpoint_blockade_and_neoantigen-based_immunotherapies/10027217 (show fewer)
Dataset
-
XPO1 expression worsens the prognosis of unfavorable DLBCL that can be effectively targeted by selinexor in the absence of mutant p53
Deng, M. (Contributor), Zhang, M. (Contributor), Xu-Monette, Z. Y. (Creator), Pham, L. V. (Creator), Tzankov, A. (Creator), Visco, C. (Creator), Fang, X. (Contributor), Bhagat, G. (Creator), Zhu, F. (Creator), Dybkaer, K. (Creator), Chiu, A. (Creator), Tam, W. (Creator), Zu, Y. (Creator), Hsi, E. D. (Creator), Choi, W. W. L. (Creator), Huh, J. (Contributor), Ponzoni, M. (Creator), Ferreri, A. J. M. (Creator), Møller, M. B. (Creator), Parsons, B. M. (Creator), van Krieken, J. H. (Contributor), Piris, M. A. (Creator), Winter, J. N. (Creator), Hagemeister, F. (Creator), Alinari, L. (Creator), Li, Y. (Creator), Andreeff, M. (Creator), Xu, B. (Creator), Young, K. H. (Creator), Manman, D. (Contributor), Xiaosheng, F. (Contributor), Zu, Y. (Creator), Jooryung, H. (Contributor), Ponzoni, M. (Creator) & Ferreri, A. J. M. (Creator), figshare, 2020
DOI: 10.6084/m9.figshare.c.5197431.v1, https://springernature.figshare.com/collections/XPO1_expression_worsens_the_prognosis_of_unfavorable_DLBCL_that_can_be_effectively_targeted_by_selinexor_in_the_absence_of_mutant_p53/5197431/1 and one more link, https://springernature.figshare.com/collections/XPO1_expression_worsens_the_prognosis_of_unfavorable_DLBCL_that_can_be_effectively_targeted_by_selinexor_in_the_absence_of_mutant_p53/5197431 (show fewer)
Dataset